Puma Biotechnology, Inc. - News Releases

Get News Alerts by RSS

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

12/19/2016

Puma Biotechnology to Move Stock Exchange Listing to Nasdaq

12/08/2016

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium

12/07/2016

Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium

12/07/2016

Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium

12/06/2016

Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States

11/14/2016

Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS)

11/09/2016

Puma Biotechnology Reports Third Quarter 2016 Financial Results

10/31/2016

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

10/25/2016

Puma Biotechnology Closes $172 Million Public Offering of Common Stock

10/21/2016

Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares

10/19/2016

Puma Biotechnology Prices Public Offering of Common Stock

10/18/2016

Puma Biotechnology Announces Proposed Public Offering of Common Stock

09/20/2016

Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

08/22/2016

Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe

08/09/2016

Puma Biotechnology Reports Second Quarter 2016 Financial Results

07/21/2016

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

07/21/2016

Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

07/07/2016

Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine

06/27/2016

Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe

06/05/2016

Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting

05/18/2016

Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting

05/17/2016

Puma Biotechnology to Present at UBS Global Healthcare Conference

05/10/2016

Puma Biotechnology Reports First Quarter 2016 Financial Results

05/04/2016

Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference

04/20/2016

Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016

04/14/2016

Puma Biotechnology’s NEfERT-T Phase II Study Published Online in JAMA Oncology

03/28/2016

Puma Biotechnology Updates Timeline for Filing New Drug Application

03/18/2016

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016

03/02/2016

Puma Biotechnology to Present at Cowen’s Health Care Conference

02/29/2016

Puma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results

02/17/2016

Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference

02/16/2016

Puma Biotechnology Announces the Conclusion and Final Results of Eshelman’s Consent Solicitation

02/11/2016

Puma Biotechnology’s ExteNET Phase III Study Published Online in The Lancet Oncology

02/03/2016

Puma Biotechnology to Participate in Fireside Chat at Leerink Partners Global Healthcare Conference

01/08/2016

Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation

01/04/2016

Puma Biotechnology to Present at J.P. Morgan Healthcare Conference